Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Dermatologic 2Sarcoma 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Testicular Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Melanoma 1Bone Neoplasms 1

Interventions

Cyclophosphamide 20pembrolizumab 19Nivolumab 10fludarabine 7Radiosurgery 7Specimen Handling 6Ipilimumab 6Injections 5Celecoxib 5poly ICLC 4Radiation 4Paclitaxel 4Melphalan 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Docetaxel 4Cryosurgery 4durvalumab 3cemiplimab 3Filgrastim 3Etoposide 3Cisplatin 3Blood Specimen Collection 3Biopsy 3trastuzumab deruxtecan 2tislelizumab 2talimogene laherparepvec 2spartalizumab 2fludarabine phosphate 2bempegaldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Histocompatibility Testing × Sarcoma × Clear all
NCT05819827 2025-04-27

Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics

Mayo Clinic

Terminated
13 enrolled
DermatologicGenitourinarySarcoma

Urinary Bladder Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡